Saturday, July 11, 2026

pharma · Coronary Artery Bypass Grafting · Hypertension Pulmonary Secondary · TENX

TENAX THERAPEUTICS

TENAX THERAPEUTICS is a pharma organization headquartered in Chapel Hill, USA. It trades on NYSE under ticker TENX. Primary therapeutic focus areas include Coronary Artery Bypass Grafting, Hypertension Pulmonary Secondar

Chapel Hill, USA HQ
19 Employees
Public company Type
TENX · NYSE Ticker
Company details
Status
Public
HQ
Chapel Hill, USA
Employees
19
Programs
7
Drugs
2
Patents
4
Clinical program

Oxycyte

Phase 2 · small molecule · Traumatic Brain Injury

Oxycyte for Traumatic Brain Injury is a Phase 2 program (small_molecule) at TENAX THERAPEUTICS, INC. with 2 ClinicalTrials.gov record(s).

← All TENAX THERAPEUTICS, INC. projects Phase 2 small molecule terminated

Internal code OX-CL-II-005

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
TENAX THERAPEUTICS, INC.
Phase
Phase 2
Modality
small_molecule
Indication
Traumatic Brain Injury
Status
terminated
Trials
2

Clinical trials